Abstracts

FETAL BIOMETRY SIMILAR WITH DOLUTEGRAVIR OR EFAVIRENZ EXPOSURE

Pregnant women living with HIV (PWLHIV) are increasingly receiving dolutegravir (DTG) worldwide and in Botswana. Few studies have assessed fetal biometry in PWLHIV on DTG-based antiretroviral therapy (ART). We evaluated fetal biometry via ultrasound in PWLHIV and HIV-uninfected (HIV-U) pregnant women enrolled in the Tshilo Dikotla cohort in Botswana. PWLHIV enrolled between 16-36 weeks gestational…

SIMILAR BIRTH ANTHROPOMETRICS WITH IN UTERO EXPOSURE TO DOLUTEGRAVIR OR EFAVIRENZ

Prior to a policy of lifetime antiretroviral treatment (ART) for all pregnant women living with HIV (WLHIV), some studies reported lower HIV-exposed uninfected (HEU) infant birth anthropometrics compared to HIV-unexposed uninfected (HUU) infants. We quantified birth anthropometrics by infant HIV exposure status in two Botswana prospective studies, where HEU infants were exposed to either dolutegravir…

ADVERSE PREGNANCY OUTCOMES IN HIV-POSITIVE PREGNANT WOMEN ON ART IN KENYA

While antiretroviral treatment (ART) is essential for the elimination of mother-to-child transmission (MTCT) and improved health outcomes for women living with HIV (WLWH) globally, adverse pregnancy outcomes (APO) among pregnant women on life-long ART are a growing concern. A total of 1225 pregnant WLWH enrolled in the Mother-Infant Visit Adherence and Treatment Engagement (MOTIVATE) study…

TIMING OF MATERNAL ANTIRETROVIRAL THERAPY INITIATION AND STILLBIRTH IN MALAWI

Studies on the use of antiretroviral therapy (ART) during pregnancy in HIV-infected women suggest that in-utero ART exposure may be associated with adverse birth outcomes, including stillbirth, preterm delivery, and being small for gestational age. Despite efforts to understand the effect of ART exposure on birth outcomes in prevention of mother-to-child transmission programs, the association…

LOPINAVIR (AN HIV PROTEASE INHIBITOR) IMPAIRS UTERINE REMODELING DURING PREGNANCY

Exposure to protease inhibitor (PI) based combination antiretroviral therapy (cART) during pregnancy; especially Lopinavir (LPV) based cART during periconception, increases the prevalence of preterm delivery and low birth weight. PIs may contribute to these adverse events by lowering progesterone (P4) levels. P4 plays a central role in uterine preparation for pregnancy, and a critical P4-dependent…

POORER CONTROL OF VIRAL LOAD IN PATIENTS INFECTED PERINATALLY VERSUS DURING ADULTHOOD

Combined antiretroviral treatment (cART) allows most HIV-infected infants to reach adulthood. We studied whether the current virological response of perinatally-infected children and young adults to cART was similar to that of patients infected during adulthood, with a similar duration of infection and treatment history. Data from 5 ongoing French national ANRS cohorts were pooled: 1)…